Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RWJ-800088 for prevention of chemotherapy-induced anemia and thrombocytopenia in non-small cell lung cancer
2007-007520-17Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-26366821 in chemotherapy-induced anaemia (CIA) and chemotherapy-induced thrombocytopenia (CIT) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence of composite anemia endpoint. Started Jun 2008; status: terminated.
02
Drugs
JNJ-26366821
03
Conditions
chemotherapy-induced anaemia (CIA)chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2007-007520-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007520-17.